# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2009 Earnings Results

**Report date:** 2009-08-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2009

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.15%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | +32.86% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a cautiously optimistic outlook regarding their ongoing projects. They emphasized the importance of their research initiatives.

**Key quotes:**

> Management highlighted ongoing research and development efforts.

> They expressed confidence in future product pipeline potential.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

Regeneron's earnings report showed a smaller-than-expected loss per share, which pleased investors and led to a 2.15% increase in the stock price. The positive EPS surprise indicates that the company is managing costs effectively despite not providing revenue figures. The management's focus on research and development suggests potential growth opportunities in the future.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2009_